

1 **Full Title: Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273**
2 **Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the**
3 **single-arm, open-label, Phase 3 SHERPA Study**

4
5 **Short Title: Safety and Effectiveness of mRNA-1273 Boost after AD26.COV2.S Prime**

6
7 **Authors:** Nigel Garrett^{1,2}, Tarylee Reddy³, Nonhlanhla Yende-Zuma³, Azwidhwi Takalani⁴,
8 Kubashni Woeber⁵, Annie Bodenstein⁶, Phumeza Jonas⁶, Imke Engelbrecht⁶, Waasila
9 Jassat⁷, Harry Moultrie⁷, Debbie Bradshaw⁸, Ishen Seocharan³, Jackline Odhiambo⁴, Kentse
10 Khuto⁴, Simone I. Richardson^{9,10}, Millicent A. Omondi¹¹, Rofhiwa Nesamari¹¹, Roanne S.
11 Keeton¹¹, Catherine Riou^{11,12}, Thandeka Moyo-Gwete^{9,10}, Craig Innes¹³, Zwelethu Zwane¹³,
12 Kathy Mngadi¹³, William Brumskine¹³, Nivashnee Naicker¹, Disebo Potloane¹, Sharlaa Badal-
13 Faesen¹⁴, Steve Innes¹⁵, Shaun Barnabas¹⁶, Johan Lombaard¹⁷, Katherine Gill¹⁵,
14 Maphoshane Nchabeleng¹⁸, Elizma Snyman¹⁹, Friedrich Petrick²⁰, Elizabeth Spooner²¹,
15 Logashvari Naidoo²¹, Dishiki Kalonji²¹, Vimla Naicker²¹, Nishanta Singh²¹, Rebone Mabo²²,
16 Pamela Mda²³, Daniel Malan²⁴, Anusha Nana²⁵, Mookho Malahleha²⁶, Philip Kotze²⁷, Jon J.
17 Allagappen²⁸, Andreas H. Diacon²⁹, Gertruida M. Kruger³⁰, Faezah Patel³¹, Penny L.
18 Moore^{1,9,10}, Wendy A. Burgers^{11,12}, Kate Anteyi³², Brett Leav³², Linda-Gail Bekker¹⁵, Glenda E
19 Gray³³, Ameena Goga^{34,35} and the SHERPA study team

20
21 **Affiliations:**

- 22 1. Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
- 23 2. Discipline of Public Health Medicine, School of Nursing and Public Health, University of
24 KwaZulu-Natal, Durban, South Africa
- 25 3. Biostatistics Research Unit, South African Medical Research Council (SAMRC), Durban,
26 South Africa
- 27 4. Hutchinson Center Research Institute of South Africa, Cape Town, South Africa
- 28 5. Grants, Innovation and Product Development Unit, SAMRC, Durban, South Africa

- 29 6. Right to Care, Johannesburg, Gauteng, South Africa
- 30 7. Division of Public Health Surveillance and Response, National Institute for
31 Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS),
32 Johannesburg, South Africa
- 33 8. Burden of Disease Research Unit, SAMRC, Tygerberg, South Africa
- 34 9. SAMRC Antibody Immunity Research Unit, School of Pathology, University of the
35 Witwatersrand, Johannesburg, South Africa.
- 36 10. Centre for HIV and STIs, NICD of the NHLS, Johannesburg, South Africa.
- 37 11. Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology,
38 Department of Pathology, University of Cape Town, Cape Town, South Africa
- 39 12. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,
40 Cape Town, South Africa
- 41 13. Aurum Institute, Johannesburg, South Africa
- 42 14. Clinical HIV Research Unit, Johannesburg, South Africa
- 43 15. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
- 44 16. Family Centre for Research with Ubuntu, Tygerberg, South Africa
- 45 17. Josha Research, Bloemfontein, South Africa
- 46 18. Medunsa Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria,
47 South Africa
- 48 19. TASK Eden, George, South Africa
- 49 20. Mzansi Ethical Research Centre, Middelburg, South Africa
- 50 21. SAMRC Clinical Research Site, Durban South Africa
- 51 22. Ndlovu Research Centre, Elandsdoorn, South Africa
- 52 23. Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa
- 53 24. PHOENIX Pharma, Port Elizabeth, South Africa
- 54 25. Perinatal HIV Research Unit, Johannesburg, South Africa
- 55 26. Synergy Biomed Research Institute, East London, South Africa
- 56 27. Qhakaza Mbokodo Research Clinic, Ladysmith, South Africa

- 57 28. Setshaba Research Centre, Soshanguve, South Africa
58 29. TASK Central, Cape Town, South Africa
59 30. Ubuntu Clinical Research, Gauteng, South Africa
60 31. Wits RHI Research Institute, University of Witwatersrand, Johannesburg, South Africa
61 32. Moderna Inc., Cambridge, MA, USA
62 33. Office of the President and CEO, SAMRC, Cape Town, South Africa
63 34. Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa
64 35. HIV and other Infectious Diseases Research Unit, SAMRC, Durban, South Africa

65

66 **Corresponding Author:** Prof Nigel Garrett; 2nd Floor, Doris Duke Medical Research
67 Institute (Private Bag X7), 719 Umbilo Road, Congela, Durban 4013, South Africa;
68 Email: nigel.garrett@caprisa.org; Phone: +27 31 655 0617

69

70 **Keywords:** SARS-CoV-2, COVID-19, Ad26.COV2.S, mRNA-1273, vaccine, booster

71

72 **Word counts:**

73 Abstract: 300/300

74 Text: 3866

75 Tables/Figures: 3 Tables and 3 Figures

76

77

78 **Abstract**

79 Given limited data on safety and effectiveness of heterologous COVID-19 vaccine boosting
80 in lower income, high-HIV prevalence settings, we evaluated a mRNA-1273 boost after
81 Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3
82 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs).
83 Sisonke participants were offered mRNA-1273 boosters between May and November 2022,
84 a period of circulating Omicron sub-lineages. Adverse events (AE) were self-reported, and
85 co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths)
86 were collected through national databases. We used Cox regression models with booster
87 status as time-varying covariate to determine the relative vaccine effectiveness (rVE) of the
88 mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248
89 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had
90 received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV
91 (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including
92 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29-76%)
93 against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.COV2.S dose group
94 and 52% (95%CI 13-73%) in the two-dose group. Severe COVID-19 was identified in 148
95 unboosted participants, and only one SHERPA participant with severe HIV-related
96 immunosuppression. Of 11798 participants in the safety analysis, 271 (2.3%) reported a
97 reactogenicity event or unsolicited AE, more among those with prior SARS-CoV-2 infections
98 (adjusted odds ratio [aOR] 2.03, 95%CI 1.59-2.59) and less among people living with HIV
99 (PLWH) (aOR 0.49, 95%CI 0.34-0.69). No related serious AEs were reported. In an
100 immunogenicity sub-study, mRNA-1273 increased antibody functions and T-cell responses 4
101 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status,
102 and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after
103 one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron
104 SARS-CoV-2 infections among HCWs and PLWH.

105

106 **Trial Registration:** The SHERPA study is registered in the Pan African Clinical Trials
107 Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial
108 Registry (SANCTR): DOH-27-052022-5778.

109

110 **INTRODUCTION**

111 During the first 2 years of the COVID-19 pandemic, populations in low- and middle-income
112 countries (LMICs) had limited access to mRNA vaccines. Instead, most LMICs including
113 South Africa, started their vaccination programmes with vector-based vaccines, such as
114 Ad26.COV2.S (Janssen/Johnson & Johnson) and ChAdOx1-S (Oxford/AstraZeneca). When
115 vaccine demand subsided in high-income countries and production increased, mRNA
116 vaccines by Pfizer-BioNTech and Moderna became available, allowing for a heterologous
117 boosting strategy in LMICs. While this strategy was supported by immunogenicity data and
118 by programmatic evaluations^{1,2}, it was not formally investigated in clinical trials, meaning
119 there was limited evidence on safety and effectiveness of mRNA booster vaccinations after
120 the Ad26.COV2.S vaccine, especially from LMICs with high HIV prevalence.

121

122 In South Africa, the COVID-19 vaccination rollout started in February 2021, when half a
123 million healthcare workers received a single dose of Ad26.COV2.S in the Sisonke phase 3b
124 implementation trial³, just before the rapid spread of the SARS-CoV-2 Delta variant. Through
125 monitoring of national COVID-19 databases, Sisonke showed that a single dose of
126 Ad26.COV2.S was 67% (95% confidence interval [CI] 62–71%) effective against COVID-19-
127 related hospitalisations and 83% (75–89%) against COVID-19-related deaths³. Following the
128 release of the ENSEMBLE 2 trial results^{4,5}, approximately half of the Sisonke participants
129 opted for a second Ad26.COV2.S dose between October and December 2021. By this time,
130 South Africa experienced a surge in SARS-CoV-2 cases with the Omicron variant. Early data
131 showed that the second Ad26.COV2.S dose provided added protection against
132 hospitalizations and deaths during the Omicron wave⁶.

133

134 Following the recommendation by the United States Food and Drug Administration to limit
135 the use of the Ad26.COV2.S vaccine, because of rare reported events of thrombosis with
136 thrombocytopenia syndrome, and emerging data showing superior neutralizing antibody
137 responses after mRNA vaccines, there was an urgent need to clarify the safety,
138 immunogenicity and effectiveness of a heterologous vaccination approach in LMICs.
139 Considering this, the Sisonke study team rapidly implemented and conducted the SHERPA
140 study nested in Sisonke to investigate a heterologous mRNA-1273 boost after one or two
141 doses of Ad26.COV2.S among healthcare workers in South Africa.

142

143

144 **METHODS AND MATERIALS**

145 *Study design and setting*

146 SHERPA (Sisonke Heterologous mRNA-1273 boost after Priming with Ad26.COV2.S) was a
147 single-arm, open-label, phase 3 study, nested in the Sisonke trial, in which healthcare
148 workers in South Africa had received one or two doses of Ad26.COV2.S between February
149 and December 2021. In SHERPA, Sisonke participants were offered a mRNA-1273 booster
150 dose (ancestral strain) at 30 clinical research sites (CRS) across South Africa, between 23
151 May 2022 and 12 November 2022. Using routinely collected national data, we aimed to
152 compare SARS-CoV-2 infections and COVID-19-related hospitalizations and deaths among
153 SHERPA participants with Sisonke participants who did not receive the mRNA-1273 booster
154 (see study schema in **Supplementary Table 1**). The data cut-off for outcome ascertainment
155 was 31 December 2022. Seven CRS followed 200 SHERPA participants for six months in a
156 safety and immunogenicity sub-study. SHERPA was registered in the Pan African Clinical
157 Trials Registry (PACTR202310615330649) and the South African National Clinical Trial
158 Registry (DOH-27-052022-5778). All participants provided written informed consent.

159

160 *Participants*

161 Sisonke participants were invited to join SHERPA via short messaging system (SMS) with a
162 study website link, where they could register and choose a convenient CRS. SHERPA
163 participants were 18 years or older with or without comorbidities, including HIV infection,
164 were employed in the South African public or private healthcare sector, and had received
165 either one or two doses of Ad26.COVID-19 in Sisonke. Considering the high COVID-19
166 morbidity among pregnant women, pregnant and breastfeeding women were eligible.
167 Sisonke participants who had received any COVID-19 vaccine other than one or two doses
168 of Ad26.COVID-19 (e.g., another mRNA booster) and those with evidence of SARS-CoV-2
169 infection within 14 days of enrolment were excluded (see **Supplementary Table 2** for full
170 eligibility criteria).

171

172 *Study procedures*

173 Once consented, the study team took a medical history, conducted a physical examination,
174 and recorded any concomitant medications. Female participants of reproductive age had a
175 pregnancy test, and all participants had a nasal swab taken for SARS-CoV-2 polymerase
176 chain reaction (PCR) testing and a plasma sample to test for SARS-CoV-2 serology before
177 vaccination. Participants in the safety and immunogenicity sub-study also had peripheral
178 blood mononuclear cells (PBMC) and plasma samples taken before mRNA-1273 booster
179 vaccination and 4 and 24 weeks after vaccination (see **Supplementary Tables 3 and 4**).

180

181 The 50mcg dose of the mRNA-1273 booster was prepared by research pharmacists. Clinical
182 research staff then administered the vaccine in the deltoid muscle, and participants were
183 monitored for 15 minutes for immediate reactogenicity events or allergic reactions. Adverse
184 events (AE) experienced at the vaccination visit were managed and recorded by the CRS
185 team. After the observation period, participants were issued with vaccination certificates, and
186 CRS and Sisonke 'Safety Desk' contact details for AE reporting. Pregnant and breastfeeding
187 women were followed up by the central safety team, through a pregnancy and breastfeeding
188 registry that both the CRS and safety teams had access to.

189

190 *Immunogenicity sub-study*

191 Plasma and PBMC samples were taken before mRNA-1273 vaccination and 4 and 24 weeks
192 after vaccination. We conducted SARS-CoV-2 spike enzyme linked immunosorbent assays
193 (ELISA), SARS-CoV-2 nucleocapsid ELISA testing, a lentiviral pseudovirus neutralization
194 assay, and an antibody-dependent cellular cytotoxicity (ADCC) assay at all timepoints.
195 Neutralizing antibody responses in people living with HIV (PLWH) were tested using a
196 vesicular stomatitis virus-based neutralization assay which was not subject to antiretroviral
197 therapy interference⁷, and which produced equivalent titers to the lentiviral assay
198 (**Supplementary Fig.1**). T-cell responses to SARS-CoV-2 spike were measured from
199 cryopreserved PBMC using intracellular cytokine staining and flow cytometry. This was
200 performed on the first 50 participants with available PBMC samples at the three sampling
201 visits (see Supplementary materials for immunogenicity assays).

202

203 *Data sources and data management*

204 We obtained SARS-CoV-2 and severity endpoint data through the surveillance system that
205 was built for Sisonke (**Supplementary Fig.2**). Data sources included the Notifiable Medical
206 Conditions Sentinel Surveillance (NMCCSS) database of SARS-CoV-2 cases, the DATCOV
207 database of reported confirmed COVID-19 hospital admissions, and the national Electronic
208 Vaccination Data System (EVDS) for COVID-19 vaccines. Automated near real-time
209 deterministic and probabilistic linkage algorithms were applied to link these three routine
210 COVID-19 datasets. Breakthrough SARS-CoV-2 infections, defined as a positive SARS-
211 CoV-2 PCR or antigen test ≥ 14 days after booster vaccination, and COVID-19
212 hospitalisations or deaths were identified through linking the databases.

213

214 SHERPA study visits were recorded in a Research Electronic Data Capture (REDCap)
215 database (Vanderbilt University, Nashville, US). After the screening/enrolment visit, solicited
216 and unsolicited AEs were self-reported via an online data entry link shared by SMS with

217 participants 1, 7 and 28 days after the booster. All safety events including Serious AEs
218 (SAE) and AEs of Special Interest (AESI) were reviewed by safety clinicians and the
219 Protocol Safety Review Team (PSRT). Data management systems were CFR Part 11 and
220 POPIA compliant and processes followed Good Clinical Data Management Processes
221 guidance.

222

223 *Variables*

224 For the relative vaccine effectiveness (rVE) analysis, we used demographic and clinical
225 variables that are routinely collected in the EVDS, including age, sex, common
226 comorbidities, and geographic location. The NMCSS database provided information about
227 previous SARS-CoV-2 infections.

228

229 *Outcomes*

230 The co-primary outcomes were to assess the rVE of the mRNA-1273 booster by comparing
231 the rates of SARS-CoV-2 infections and severe COVID-19 cases (defined as COVID-19
232 hospitalizations or deaths) among SHERPA participants compared to unboosted Sisonke
233 participants. Secondary outcomes included an assessment of rVE of the mRNA-1273
234 booster against SARS-CoV-2 Infections, COVID-19 hospitalizations and deaths, in those
235 who had received one or two doses of Ad26.COVS.S separately; an assessment of safety of
236 the mRNA-1273 boost, including among pregnant women and PLWH; and comparisons of
237 antibody and T-cell responses before and after vaccination.

238

239 *Statistical analysis*

240 Analyses for the primary and secondary outcomes were performed using SAS version 9.4
241 (Statistical Analysis Software, North Carolina, USA) and Stata version 17 (College Station,
242 TX, USA). Demographic and clinical data of participants enrolled in SHERPA and Sisonke
243 were summarized using descriptive statistics including frequencies, proportions, and
244 medians with interquartile ranges (IQR). For the primary analysis, we used a statistical

245 method proposed by Fintzi and Follmann⁸ referred to here as an adjusted cohort approach,
246 which allowed inclusion of SHERPA participants within the larger Sisonke cohort
247 **(Supplementary Fig.3)**.

248

249 We used a Cox regression model with the mRNA-1273 booster status as a time-varying
250 covariate, adjusting for age, sex, an indicator of whether a participant had previously
251 received one or two doses of Ad26.COVS, geographic location, number of comorbidities
252 and evidence of prior SARS-CoV-2 infection. This time-varying exposure was characterized
253 by a continuous piecewise linear function of time elapsed since the first mRNA-1273 dose
254 (23 May 2022) for the log hazard ratio. Participants who did not experience an event of
255 interest were censored on 31 December 2022 (cut-off date). The rVE in reducing the risk of
256 SARS-CoV-2 infection and COVID-19 hospitalizations and deaths was estimated as one
257 minus the estimated hazard ratio with 95% CI. Further details regarding outcome analyses,
258 including an alternative matched cohort analysis approach, definitions of variables, and
259 immunogenicity analyses are detailed in the **Statistical Analysis Plan**.

260

261 *Study approvals*

262 The SHERPA and Sisonke trial protocols were approved by the South African Health
263 Products Regulatory Authority (SAHPRA), and health research ethics committees of all
264 participating CRSs. The study received full ethical approval by the following ethics
265 committees in South Africa: Pharma-Ethics, Stellenbosch University Health Research Ethics
266 Committee, University of KwaZulu-Natal Biomedical Research Ethics Committee, University
267 of Cape Town Human Research Ethics Committee, Sefako Makgatho University Research
268 Ethics Committee, The South African Medical Research Council Human Research Ethics
269 Committee and the University of the Witwatersrand Human Research Ethics Committee.

270

271

272

273 **RESULTS**

274 *Study Population*

275 Of 501230 Sisonke participants who had received one or two Ad26.COVID.S doses between
276 17 February 2021 and 22 May 2022, 12342 enrolled into SHERPA and received the mRNA-
277 1273 booster between 23 May 2022 and 12 November 2022 (**Fig.1**). Of these, 1094 (8.9%)
278 were excluded from the rVE analysis, because they had either received a third
279 Ad26.COVID.S or a BNT162b2 mRNA booster, or had received an Ad26.COVID.S vaccine
280 after the earliest date of mRNA-1273 vaccination on 23 May 2022. Participants at one CRS
281 had to be excluded from rVE and safety analyses due to concerns about data integrity. The
282 mRNA-1273 booster rVE analysis included 11248 SHERPA participants, of whom 5102
283 (45.4%) had received one and 6146 (54.6%) two prior Ad26.COVID.S doses. These were
284 compared to 413161 non-SHERPA Sisonke participants, of whom 185676 (44.9%) had
285 received one and 227485 (55.1%) two doses of Ad26.COVID.S.

286

287 **Figure 1: Flow Chart of the SHERPA Analysis Cohort nested in the Sisonke**

288 **Implementation Trial**

289

290 Baseline demographic and clinical characteristics of the SHERPA and non-SHERPA
291 participants stratified by number of previous Ad26.COVID.S vaccinations are summarized in
292 **Table 1**. The majority (79.3%) of SHERPA participants were female and median age was 41
293 years (IQR 35–48). One third (32.2%) of participants reported at least one comorbidity, most
294 commonly HIV infection (18.7%), hypertension (12.9%) and diabetes (4.6%). Participants
295 were recruited from all nine South African provinces. Non-SHERPA participants had similar
296 characteristics, apart from fewer reporting HIV infection (8.3%).

297

298

299

300 **Table 1: Baseline Demographics and clinical Characteristics of SHERPA and non-**
 301 **SHERPA Participants previously vaccinated in Sisonke**

Characteristic	SHERPA			non-SHERPA		
	Ad26.COVS.S + mRNA-1273 (N=5102)	2 Ad26.COVS.S + mRNA-1273 (N=6146)	Total (N=11248)	Ad26.COVS.S (N=185676)	2 Ad26.COVS.S (N=227485)	Total (N= 413161)
Sex, n (%)						
Female	4048 (79.3%)	4877 (79.4%)	8925 (79.3%)	136534 (73.5%)	171854 (75.5%)	308388 (74.6%)
Male	1054 (20.7%)	1269 (20.6%)	2323 (20.7%)	49142 (26.5%)	55631 (24.5%)	104773 (25.4%)
Median age (years), IQR	40 (33-46)	43 (36-50)	41 (35-48)	40 (33-49)	44 (35-53)	42 (34-51)
Age groups (year), n (%)						
18-39	2538 (49.7%)	2297 (37.4%)	4835 (43.0%)	90048 (48.5%)	83720 (36.8%)	173768 (42.1%)
40-49	1743 (34.2%)	2288 (37.2%)	4031 (35.8%)	53390 (28.8%)	68471 (30.1%)	121861 (29.5%)
50-59	699 (13.7%)	1257 (20.5%)	1956 (17.4%)	31549 (17.0%)	53257 (23.4%)	84806 (20.5%)
≥60	122 (2.4%)	304 (4.9%)	426 (3.8%)	10628 (5.7%)	22034 (9.7%)	32662 (7.9%)
Missing	0	0	0	61 (<0.1%)	3 (<0.1%)	64 (<0.1%)
Number of comorbidities, n (%)						
0	3573 (70.0%)	4048 (65.9%)	7621 (67.8%)	141683 (76.3%)	166384 (73.1%)	308067 (74.6%)
1	1334 (26.1%)	1792 (29.2%)	3126 (27.8%)	37390 (20.1%)	50328 (22.1%)	87718 (21.2%)
≥2	195 (3.8%)	304 (4.9%)	501 (4.5%)	6603 (3.6%)	10773 (4.7%)	17376 (4.2%)
Risk factors for severe COVID-19, n (%)						
Living with HIV	977 (19.1%)	1122 (18.3%)	2099 (18.7%)	17612 (9.5%)	16572 (7.3%)	34184 (8.3%)
Hypertension	541 (10.6%)	912 (14.8%)	1453 (12.9%)	23007 (12.4%)	38094 (16.7%)	61101 (14.8%)
Diabetes	188 (3.7%)	332 (5.4%)	520 (4.6%)	8382 (4.5%)	14471 (6.4%)	22853 (5.5%)
Cancer	5 (0.1%)	15 (0.2%)	20 (0.2%)	355 (0.2%)	680 (0.3%)	1035 (0.3%)
Tuberculosis	10 (0.2%)	12 (0.2%)	22 (0.2%)	236 (0.1%)	209 (0.1%)	445 (0.1%)
Heart disease	9 (0.2%)	26 (0.4%)	35 (0.3%)	974 (0.5%)	1661 (0.7%)	2635 (0.6%)
Chronic lung disease	5 (0.1%)	14 (0.2%)	19 (0.2%)	481 (0.3%)	901 (0.4%)	1382 (0.3%)
Geographical location, n (%)						
Eastern Cape	762 (14.9%)	838 (13.6%)	1600 (14.2%)	25454 (13.7%)	24773 (10.9%)	50227 (12.2%)
Free State	209 (4.1%)	308 (5.0%)	517 (4.6%)	8123 (4.4%)	11926 (5.2%)	20049 (4.9%)
Gauteng	1884 (36.9%)	1918 (31.2%)	3802 (33.8%)	51952 (28.0%)	61629 (27.1%)	113581 (27.5%)
KwaZulu-Natal	1255 (24.6%)	1464 (23.8%)	2719 (24.2%)	41449 (22.3%)	39044 (17.2%)	80493 (19.5%)

Limpopo	63 (1.2%)	93 (1.5%)	156 (1.4%)	11188 (6.0%)	17517 (7.7%)	28705 (6.9%)
Mpumalanga	227 (4.4%)	187 (3.0%)	414 (3.7%)	10140 (5.5%)	9107 (4.0%)	19247 (4.7%)
North West	184 (3.6%)	213 (3.5%)	397 (3.5%)	9073 (4.9%)	10875 (4.8%)	19948 (4.8%)
Northern Cape	4 (0.1%)	1 (0.0%)	5 (0.0%)	3251 (1.8%)	4701 (2.1%)	7952 (1.9%)
Western Cape	514 (10.1%)	1124 (18.3%)	1638 (14.6%)	25046 (13.5%)	47913 (21.1%)	72959 (17.7%)

302

303

304 *Prior SARS-CoV-2 infections and time since last vaccination*

305 Participants were checked against the NMCSS database for evidence of previous SARS-
306 CoV-2 infection. Among SHERPA participants 1079 (9.2%) had evidence of a previous
307 SARS-CoV-2 infection compared to 54770 (13.3%) among the non-SHERPA group. Overall,
308 these estimates were likely an underestimate considering higher self-report rates (28%) and
309 evidence of high prevalence of baseline seropositivity in the immunogenicity sub-study. The
310 median days between the last Ad26.COVID.S dose and 23 May 2022 (SHERPA start) was
311 188 days (IQR 171-419) among SHERPA participants and 189 days (IQR 172-406) among
312 the non-SHERPA group (**Table 2**).

313

314

315

316

317

318

319

320

321

322

323

324

325 **Table 2: Recorded prior COVID-19 Infections among SHERPA and non-SHERPA**

326 **Participants nested in the Sisonke Study**

Characteristic	SHERPA			non-SHERPA		
	Ad26.COVS.2.S + mRNA-1273 (N=5102)	2 Ad26.COVS.2.S + mRNA-1273 (N=6146)	Total (N=11248)	Ad26.COVS.2.S (N=185676)	2 Ad26.COVS.2.S (N=227485)	Total (N= 413161)
Documented previous SARS- CoV-2 infection*	398 (7.8%)	629 (10.2%)	1027 (9.2%)	21480 (11.6%)	33290 (14.6%)	54770 (13.3%)
Recent prior infection [#]	20 (0.4%)	77 (1.2%)	97 (0.9%)	2422 (1.3%)	6945 (3.1%)	9367 (2.3%)
Non-recent prior infection ⁺	378 (7.4%)	552 (9.0%)	930 (8.3%)	19058 (10.3%)	26345 (11.6%)	45403 (11.0%).
Days between last Ad26.COVS.2.S dose and (i) earliest date of a participant receiving the mRNA-1273 (SHERPA group) or (ii) enrolment as a comparator (non-SHERPA group)						
Median, IQR	424 (382 - 443)	172 (153 - 181)	188 (171 - 419)	418 (378 - 437)	173 (159 - 182)	189 (172 - 406)

327

328 *Infection on or before 23 May 2022; Both PCR and antigen tests considered.

329 [#]Recent infection means less ≤ 90 days before enrollment for SHERPA participants and < 90 days
330 before SHERPA study start 23 May 2022 for non-SHERPA participants.

331 ⁺Non- recent infection means less > 90 days before enrollment for SHERPA participants and > 90
332 days before non-SHERPA participants study start 23 May 2022 for non-SHERPA participants.

333

334 *SARS-CoV-2 infection and severe COVID-19 endpoints*

335 As of 31 December 2022, after 3056 person-years of follow up, there were 13 recorded
336 SARS-CoV-2 infections among SHERPA participants at median 125 days (IQR 90-154) after
337 mRNA-1273 boosting. In contrast, 3352 infections were recorded among the non-SHERPA
338 group after 251104 years of follow-up (**Supplementary Table 5**). There were 148 COVID-19
339 hospitalization or deaths among the non-SHERPA group compared to one among SHERPA
340 participants. This immunocompromised PLWH, with a CD4 count of less than 200 cells/mm³

341 and high HIV viremia, died of COVID-19 pneumonia with respiratory distress syndrome, six
 342 months after receiving the mRNA-1273 booster.

343

344 *Relative vaccine effectiveness of the mRNA-1273 booster*

345 Comparing SHERPA participants to the non-SHERPA group, the unadjusted analysis
 346 showed a rVE of 59% (95%CI 29-76%) against SARS-CoV-2 infection, which did not change
 347 after adjusting for age, sex, prior SARS-CoV-2 infection, prior vaccination and geographic
 348 location (**Table 3**). The adjusted rVE of the booster among participants who had one prior
 349 Ad26.COVID.S dose was 77% (95%CI 9-94%) and 52% (95%CI 13-73%) for those who had
 350 two prior Ad26.COVID.S doses. In a separate model adjusting for HIV the rVE estimate only
 351 slightly changed to 57% (95%CI 25-75%). With only one severe COVID-19 case among
 352 SHERPA participants and few severe endpoints overall, the rVE estimate for COVID-19
 353 hospitalizations and deaths lacked precision (**Supplementary Table 6**). In the alternative
 354 matched cohort analysis, the overall rVE against SARS-CoV-2 infection was slightly higher
 355 at 63% (95%CI 32-82%) (**Supplementary Tables 7 and 8**).

356

357 **Table 3: Relative Vaccine Effectiveness of mRNA-1273 Booster against SARS-CoV-2**
 358 **Infection**

	Unadjusted	Adjusted*: Model with comorbidities
	VE (95% CI)	VE (95% CI)
Primary Endpoint		
SARS-CoV-2 Infection	59% (29 - 76%)	59% (29 - 76%)
Secondary Endpoints		
SARS-CoV-2 infections after 1 previous Ad26.COVID.S	77% (8 - 94%)	77% (9 - 94%)
SARS-CoV-2 infections after 2 previous Ad26.COVID.S	51% (13 - 73%)	52% (13 - 73%)

359

360 *Adjusted for age, sex, prior COVID, prior vaccination, geographical location

361

362 *Safety profile of mRNA-1273 booster*

363 Of 11798 SHERPA participants included in the safety analysis, 228 (1.9%) participants
364 reported 575 reactogenicity events within 7 days after the mRNA-1273 booster. Of these,
365 230/575 (40%) were local reactogenicity events including 97/230 (42.2%) injection site pain,
366 69/230 (30%) swelling, 32/230 (13.9%) induration and 32/230 (13.9%) erythema events. A
367 total of 345 systemic reactogenicity events were reported including 123 (35.7%) malaise
368 and/or myalgia, 120 (34.8%) headache, 66 (19.1%) fever, 17 (4.9%) chills, 10 (2.9%)
369 nausea, 5 (1.4%) vomiting and 4 (1.2%) arthralgia. All reported local and systemic
370 reactogenicity were mild or moderate (grade 1 or 2) and all resolved without sequelae.

371

372 Unsolicited AEs collected for 28 days after vaccination and those meeting SAE/AESI criteria
373 collected until the end of study participation were reported by 98 (0.8%) participants,
374 reporting a total of 115 events. Of these events, 17 events met SAE criteria. Three of the 17
375 SAEs also met AESI criteria, the other 4 AESIs were grade 1 and 2 anosmia and ageusia,
376 which resolved without sequelae. No related SAEs were reported during the study.

377

378 More reactogenicity events were reported by participants with prior SARS-CoV-2 infection
379 (3.6% vs 1.8%), HIV-negative status (2.7% vs 1.2%) and those who received two compared
380 to one prior Ad26.COVID.S dose (2.6% vs 2.0%). In a logistic regression model adjusting for
381 age and sex, a prior SARS-CoV-2 infection (adjusted odds ratio [aOR] =2.03, 95%CI 1.59-
382 2.59) and an HIV positive status (aOR=0.49, 95%CI 0.34-0.69) were associated with
383 local/systemic reactions, but not having received two versus one Ad26.COVID.S dose before
384 the mRNA-1273 booster (aOR=1.26, 95%CI 0.99-1.62), **Supplementary Table 9**.

385

386 Among 70 confirmed pregnancies, there were 39 (55.7%) full-term births, 4 (5.7%) preterm
387 births (<37 weeks gestation), 11 (15.7%) early miscarriages (<12 weeks gestation), 7
388 (10.0%) stillbirths (>20 weeks gestation), and one (1.4%) ectopic pregnancy. Six (8.6%)

389 women opted for an elective termination of pregnancy and two (2.9%) were lost to follow-up.
390 All adverse outcomes, including miscarriages, preterm births and stillbirths were evaluated
391 and deemed unrelated to vaccination by CRS investigators and the PSRT. Preterm births
392 were reported in women with hypertension in pregnancy and multiple gestations, while the
393 stillbirths (experienced by women aged 32 to 44 years) were evaluated as associated with
394 abruptio placenta, postdate, cord around the fetal neck, and complicated home delivery
395 **(Supplementary Table 10)**.

396

397 *Immune responses after mRNA-1273 booster*

398 Baseline neutralizing antibody titers were 2-3 fold higher in participants who had received 2
399 doses versus 1 dose of Ad26.COV2.S (median: 1311 vs 3269 for D614G and 508 vs 1281
400 for BA.4) **(Fig. 2A,B)**. The mRNA-1273 boost resulted in increased neutralizing antibodies
401 titers for D614G after 4 weeks and then a decline by 24 weeks among those with one and
402 two doses of Ad26.COV2.S (median baseline, 4-week and 24-week titers of 1311, 7033 and
403 2220 for the 1-dose group and 3269, 17653, 5526 for the 2-dose group), **Fig. 2A-C**. The
404 antibody response after boosting was less pronounced towards the BA.4 pseudovirus
405 despite a significant increase in rVE against this variant of concern. Baseline spike-binding
406 antibody titers were comparable regardless of the number of previous Ad26.COV2.S doses.
407 Binding titers significantly increased up to 6-fold 4 weeks post-boost **(Fig. 2D,E)**, while
408 ADCC had smaller but significant increases post-boost **(Fig. 2F,G)**. The binding and ADCC
409 titers were lower 6 months after the boost, with similar titers observed between both
410 Ad26.COV2.S groups **(Fig. 2D-G)**. At baseline, PLWH had up to 3-fold lower binding
411 antibody titers and up to 2-fold lower neutralizing activity against D614G compared to HIV
412 negative participants, irrespective of prior Ad26.COV2.S doses, while ADCC levels were
413 similar **(Supplementary Fig.4)**. Antibody functions in PLWH followed similar trends after the
414 booster as HIV-negative participants.

415

416

417 **Figure 2: Antibody Response elicited after mRNA-1273 heterologous Boost**

418 **Legend:** *Plasma from a subset of participants were assessed to determine the antibody*
419 *response elicited upon heterologous boost (mJnJ) after 1 Ad26.COVS dose (JnJ x1; n=19)*
420 *or 2 Ad26.COVS doses (JnJ x2; n=29). The neutralization activity was measured using a*
421 *SARS-CoV-2 pseudovirus-based neutralization assay with (panel A) D614G, (panel B)*
422 *Omicron BA.4 and (panel C) D614G in people living with HIV (PLWH). The plasma*
423 *neutralization titer is measured as an ID₅₀. Black horizontal bars represent medians. The*
424 *threshold of detection for the neutralization assay is an ID₅₀ of 20. Antibody binding was*
425 *measured using an in-house SARS-CoV-2 assay using the D614G full spike protein (panel D*
426 *and E). An EC₅₀ was used to measure the binding titers of the samples. ADCC activity was*
427 *measured by detecting the crosslinking ability of the antibodies present in the serum (panel*
428 *F and G). Relative light units were measured which correlate with the levels of FcγRIIIa*
429 *signalling. For all assays, statistical significance was measured with the Kruskal-Wallis test*
430 *with Dunn's multiple comparisons test. Significance is shown as: *p < 0.05, **p < 0.01, ***p <*
431 *0.001 and ****p < 0.0001. Medians and fold changes are depicted under each graph.*
432 *Samples were run in duplicate for all assays. Nucleocapsid ELISA was used to identify prior*
433 *SARS-CoV-2 infections. Only individuals who were seropositive at baseline were included in*
434 *the analysis as there was only 1 nucleocapsid-seronegative participants in the JnJ x1 group.*

435

436 We examined T-cell responses in a subset of 50 participants (**Fig. 3A**). At baseline, spike-
437 specific CD4+ T-cell responses were detected in 96% of participants (**Fig. 3B**). Four weeks
438 after mRNA-1273 boosting, the frequency increased 2-fold (median: 0.074% vs 0.169%,
439 p<0.0001), followed by contraction to a median of 0.113% by 24 weeks, which was not
440 significantly different from baseline. Spike-specific CD8+ T-cell responses occurred in 52%
441 of participants at baseline, and followed a similar trajectory as CD4 responses, increasing
442 significantly at 4 weeks (median: 0.034% vs 0.057%, p=0.0029; **Fig. 3C**) and waning to
443 0.047% by 24 weeks. When examining the effect of prior vaccination with Ad26.COVS
444 (**Fig. 3D**), there were significantly higher CD4+ responses at baseline in those who received

445 two compared to one prior dose, which persisted at all timepoints after mRNA-1273
446 boosting. In contrast, the magnitude of CD8+ responses was similar between those who
447 received one or two Ad26.COVS.S doses. HIV infection had no negative impact on vaccine
448 booster responses at 4 or 24 weeks (**Fig. 3E**). When examining T-cell cross-reactivity to
449 Omicron sub-lineages, we observed a high degree of preservation of the T-cell responses to
450 Omicron BA.1, BA.4/5 and XBB.1 (**Fig. 3F-G**).

451

452 **Figure 3: T-cell Response elicited after mRNA-1273 heterologous Boost**

453 **Legend:** (A) Clinical characteristics of the T-cell sub-study cohort. Frequency of spike-
454 specific CD4+ (B) and CD8+ (C) T-cells producing any of the measured cytokines (IFN- γ , IL-
455 2 or TNF- α) in response to stimulation with a peptide pool spanning ancestral spike protein
456 at baseline (BL), week 4 (W4) and week 24 (W24), in participants vaccinated with one or two
457 prior doses of Ad26.COVS.S and an mRNA-1273 booster. The median response and
458 proportion of participants with a spike-specific CD4+ or CD8+ T-cell responses are indicated
459 below the graphs. (D) Spike-specific CD4+ and CD8+ T-cell cytokine responses stratified
460 according to number of Ad26.COVS.S doses received. (E) Spike CD4+ and CD8+ T-cells in
461 HIV-uninfected participants (pink) or PLWH (red). (F) Spike-specific CD4+ T-cell responses
462 to spike from ancestral virus and Omicron sub-lineages BA.1, BA.4/5 and XBB.1. (G) Fold
463 change of Omicron sub-lineage responses compared to ancestral spike. Bars represent the
464 medians. Differences between responses at different time points post boost were assessed
465 using a two-tailed Wilcoxon paired test. Differences between participants vaccinated with
466 one or two doses of Ad26.COVS.S and responses to different SARS-CoV-2 variants were
467 calculated using a Mann-Whitney U test. The number of participants included in each
468 analysis is indicated on the graphs.

469

470

471

472 **DISCUSSION**

473 Nested in the Sisonke phase 3b implementation study, the SHERPA trial showed that one
474 mRNA-1273 booster administered after 1 or 2 doses of Ad26.COVID.2.S was safe and well
475 tolerated regardless of HIV status, comorbidities or prior SARS-CoV-2 infection. The mRNA-
476 1273 booster had a rVE of 59% (29-76%) in preventing SARS-CoV-2 infections overall, 77%
477 (9-94%) after one Ad26.COVID.2.S dose and 52% (13-73%) after 2 Ad26.COVID.2.S doses up to
478 7 months after the boost. Breakthrough infections occurred during the Omicron wave
479 (**Supplementary Fig. 5**), thus the data confirm the benefit of heterologous mRNA-1273
480 boosting after priming with Ad26.COVID.2.S against Omicron sub-lineages.

481

482 The additional benefit of the mRNA-1273 booster was particularly high among participants
483 who had only received a single Ad26.COVID.2.S previously, also indicating that the booster
484 was especially effective among those who had received their vaccine dose more than a year
485 previously. This finding also corroborated with strong antibody and T-cell immune responses
486 elicited by the booster in the immunogenicity sub-study. Consistent with epidemiological data
487 on the evolving COVID-19 pandemic, few severe COVID-19 cases were detected in the
488 Sisonke cohort and only a single case among SHERPA participants, thereby not providing
489 sufficient statistical power for a meaningful interpretation of rVE against COVID-19
490 hospitalizations and deaths.

491

492 Our findings for heterologous boosting corroborate with studies reporting on homologous
493 mRNA-1273 boosting in the USA. In one study the rVE of a homologous mRNA-1273 boost
494 against SARS-CoV-2 infection was 61% (95%CI 60–62%) among immunocompetent adults
495 receiving the booster ≥ 150 days after priming during the Omicron wave⁹. In a second study
496 amongst US veterans receiving a third homologous mRNA-1273 booster during the Omicron
497 wave, the rVE was 64% (95%CI 63-65%) compared with a rVE of 12% (95%CI 10-15%) for
498 2-dose vaccination¹⁰.

499

500 Earlier in the pandemic, studies assessed the VE of a heterologous prime-boost approach.
501 One study from Sweden with 16402 participants receiving ChAdOx1 nCoV-19 prime
502 followed by a mRNA-1273 boost found a VE of 79% (95%CI, 62-88%) against symptomatic
503 COVID-19 infection compared with unvaccinated controls during the Delta wave¹¹. An almost
504 identical rVE was found in a study conducted across emergency departments in the USA for
505 people who received a single Ad26.COVS dose followed by a mRNA-1273 boost¹².
506
507 Our findings indicate that in LMICs where vaccine availability has been limited and HIV
508 prevalence, co-morbidities and prior SARS-CoV-2 infection are high, a heterologous mRNA-
509 1273 boost, using ancestral vaccine after one or two Ad26.COVS vaccinations was
510 protective against SARS-CoV-2 infection in healthcare workers during the Omicron wave.
511 Our data also confirms the safety of an mRNA-1273 boost after Ad26.COVS priming
512 amongst healthcare workers, including PLWH, people with comorbidities and pregnant
513 women.
514
515 Previous epidemiological studies on pregnancy outcomes and placental studies have shown
516 that mRNA vaccines are safe in pregnancy and that there is negligible uptake and
517 inflammatory responses within placental tissues post vaccination^{13,14,15}. In South Africa, only
518 68.3% of pregnant women have their first antenatal visit before 20 weeks gestation¹⁶,
519 meaning that national data on early pregnancy losses are limited. However, early pregnancy
520 losses observed in SHERPA (15.7%) were comparable to other clinical trial cohorts (6.1-
521 17.9%), which included early pregnancy testing and pregnancy outcome tracking^{17,18}.
522 Stillbirths reported in this study (10.0%) were associated with polymorbid conditions,
523 including abruptio placenta, cord round the fetal neck and postdate, that provided clear
524 alternative causes to the occurrence of the events. While the stillbirth rate was higher than in
525 two clinical trial cohorts among younger, HIV negative women in HIV vaccine trials (1.5-
526 3.5%), our data are in keeping with a 10% increase in stillbirths noted nationally in recent

527 review periods¹⁹, as well as the generally higher stillbirth rates reported among older cohorts
528 and cohorts of PLWH^{20,21,22}.

529

530 Antibody responses were higher among participants with two compared to one prior
531 Ad26.COVID.S dose and were boosted with a heterologous mRNA vaccine among both
532 groups, as reported previously^{2,23,24}. Despite some evidence that Ad26.COVID.S may lead to
533 slower waning of immune responses than mRNA vaccines^{25,26}, the decline of antibody
534 responses at 6 months in SHERPA suggests that the Ad26.COVID.S as a primary dose(s)
535 may not significantly increase the durability of mRNA-boosted antibody responses. Although
536 PLWH had lower antibody responses at baseline, mRNA-1273 boosting resulted in
537 comparable titers to HIV-negative participants. mRNA-1273 boosting increased spike-
538 specific T-cell responses, as described previously for heterologous vaccination regimens^{2,27}.
539 These responses were durable and highly cross-reactive to Omicron sub-lineages.

540

541 SHERPA had some limitations. First, it was a single arm trial nested in the larger Sisonke
542 trial. As in Sisonke, we relied on routinely collected data to ascertain COVID-19 endpoints.
543 However, this applied to both mRNA-1273 boosted and unboosted study groups, therefore
544 reducing the potential for reporting bias. Second, we observed too few severe COVID-19
545 endpoints to allow for a well-powered assessment of rVE against severe disease.

546 Contributing factors could have been that SHERPA was conducted during the Omicron
547 wave, when generally less severe disease was reported²⁸, South Africa has a high SARS-
548 CoV-2 seroprevalence of up to 80%²⁹, and all participants had at least received one dose of
549 Ad26.COVID.S previously. Finally, we were unable to compare pregnancy outcomes in the
550 SHERPA study with the larger Sisonke trial population, because pregnant women were
551 initially not eligible for Sisonke, and pregnancy outcomes were not systematically collected.

552

553 Our data show that a heterologous mRNA-1273 boost following one or two Ad26.COVID.S
554 priming among healthcare workers including those with HIV, comorbidities and pregnancy

555 can be included in national policy. We also demonstrate that boosting with the ancestral
556 mRNA-1273 vaccine is still effective despite the evolution of SARS-CoV-2 into Omicron sub-
557 lineage. This is important as variant vaccines may not be accessible in these settings. In
558 conclusion, the SHERPA trial showed a high rVE of the mRNA-1273 booster during the
559 Omicron wave among healthcare workers who had received one or two previous doses of
560 Ad26.COV2.S. The heterologous booster was safe and well tolerated, immunogenic and
561 effective in a LMIC with high HIV prevalence.

562

563 **Declaration of Interests**

564 KA and BL are employees of Moderna, Inc. and may hold stock/stock options in the
565 company. The other authors declare no conflict of interests.

566

567 **Authorship contributions**

568 **Conceptualization:** Nigel Garrett, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

569 **Data curation:** Nigel Garrett, Azwidhwi Takalani, Annie Bodenstein, Phumeza Jonas, Imke

570 Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Simone I. Richardson,

571 Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka

572 Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee

573 Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan

574 Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick,

575 Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh,

576 Rebone Maboja, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip

577 Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faezah Patel, Penny L.

578 Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

579 **Formal analysis:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Ishen

580 Seocharan, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S.

581 Keeton, Catherine Riou, Thandeka Moyo-Gwete, Penny L. Moore, Wendy A. Burgers

582 **Funding acquisition:** Nigel Garrett, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

583 **Investigation:** Nigel Garrett, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Simone
584 I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,
585 Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine,
586 Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas,
587 Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich
588 Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta
589 Singh, Rebone Maboja, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha,
590 Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faezah Patel,
591 Penny L. Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga
592 **Methodology:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Waasila Jassat,
593 Harry Moultrie, Ishen Seocharan, Jackline Odhiambo, Penny L. Moore, Wendy A. Burgers,
594 Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga
595 **Project administration:** Nigel Garrett, Azwidhwi Takalani, Kubashni Woeber, Ishen
596 Seocharan, Jackline Odhiambo, Kentse Khuto, Kate Anteyi, Linda-Gail Bekker, Glenda E
597 Gray, Ameena Goga
598 **Resources:** Harry Moultrie, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav,
599 Glenda E Gray
600 **Supervision:** Nigel Garrett, Azwidhwi Takalani, Penny L. Moore, Wendy A. Burgers, Linda-
601 Gail Bekker, Glenda E Gray, Ameena Goga
602 **Validation:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Penny L. Moore,
603 Wendy A. Burgers
604 **Visualization:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Simone I.
605 Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,
606 Thandeka Moyo-Gwete
607 **Writing – original draft:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Thandeka
608 Moyo-Gwete, Penny L. Moore, Wendy A. Burgers, Ameena Goga
609 **Writing – review & editing:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma,
610 Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke

611 Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline
612 Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
613 Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane,
614 Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-
615 Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane
616 Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo,
617 Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan,
618 Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon,
619 Gertruida M. Kruger, Faezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett
620 Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

621

622 **Funding**

623 The SHERPA study was funded by Moderna, Inc. (Cambridge, Massachusetts, US) and the
624 South African Medical Research Council (SAMRC). Moderna provided mRNA-1273 free-of-
625 charge. The Sisonke trial was funded by: The National Department of Health through
626 baseline funding to the SAMRC; the Solidarity Response Fund NPC; The Michael & Susan
627 Dell Foundation; the ELMA Vaccines and Immunization Foundation (21-V0001); and the Bill
628 & Melinda Gates Foundation (INV-030342). Moderna representatives reviewed the study
629 protocol, participated in safety oversight, and contributed as manuscript co-authors, but were
630 not involved in data collection and analysis.

631

632 **Acknowledgements**

633 We thank the participants, the protocol and safety teams, the site-Principal Investigators,
634 and their teams, the laboratory teams, SAHPRA, and the ethics committees for their
635 contribution and oversight of the study.

636

637

638 **References**

- 639 1. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
640 Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 641 2. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19
642 Booster Vaccinations. *N Engl J Med* 2022; **386**(11): 1046-57.
- 643 3. Bekker LG, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in
644 health-care workers in South Africa (the Sisonke study): results from a single-arm,
645 open-label, phase 3B, implementation study. *Lancet* 2022; **399**(10330): 1141-53.
- 646 4. Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a
647 booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results
648 of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Infect Dis*
649 2022; **22**(12): 1703-15.
- 650 5. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose
651 Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**(23): 2187-201.
- 652 6. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2
653 Vaccines against Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(23): 2243-
654 5.
- 655 7. Bewley KR, Coombes NS, Gagnon L, et al. Quantification of SARS-CoV-2 neutralizing
656 antibody by wild-type plaque reduction neutralization, microneutralization and
657 pseudotyped virus neutralization assays. *Nat Protoc* 2021; **16**(6): 3114-40.
- 658 8. Fintzi J, Follmann D. Assessing vaccine durability in randomized trials following
659 placebo crossover. *Stat Med* 2021; **40**(27): 5983-6007.
- 660 9. Florea A, Sy LS, Qian L, et al. Effectiveness of Messenger RNA-1273 Vaccine Booster
661 Against Coronavirus Disease 2019 in Immunocompetent Adults. *Clin Infect Dis* 2023;
662 **76**(2): 252-62.

- 663 10. Young-Xu Y, Zwain GM, Izurieta HS, et al. Effectiveness of mRNA COVID-19 vaccines
664 against Omicron and Delta variants in a matched test-negative case-control study
665 among US veterans. *BMJ Open* 2022; **12**(8): e063935.
- 666 11. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19
667 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in
668 Sweden: A nationwide cohort study. *Lancet Reg Health Eur* 2021; **11**: 100249.
- 669 12. Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and
670 Heterologous COVID-19 Booster Doses Following 1 Ad.26.COVS.2.S (Janssen
671 [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency
672 Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION
673 Network, 10 States, December 2021-March 2022. *MMWR Morb Mortal Wkly Rep*
674 2022; **71**(13): 495-502.
- 675 13. Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. mRNA Covid-
676 19 vaccines in pregnancy: A systematic review. *PLoS One* 2022; **17**(2): e0261350.
- 677 14. Magnus MC, Ortqvist AK, Dahlgvist E, et al. Association of SARS-CoV-2 Vaccination
678 During Pregnancy With Pregnancy Outcomes. *JAMA* 2022; **327**(15): 1469-77.
- 679 15. Gonzalez VJ, Li L, Buarpong S, Prah M, Robinson JF, Gaw SL. Minimal mRNA
680 uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human
681 placental explants. *iScience* 2023; **26**(9): 107549.
- 682 16. Africa SS. The Status of women in South Africa: Evidence from selected indicators,
683 2022.
- 684 17. Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for
685 prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3,
686 randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2018; **18**(11):
687 1241-50.

- 688 18. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili
689 study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised,
690 placebo-controlled test-of-concept phase 2b study. *Lancet Infect Dis* 2011; **11**(7): 507-
691 15.
- 692 19. Pattinson R FS, Gebhardt S, Soma-Pillay P, Niit R, Moodley J. The impact of COVID-
693 19 on use of maternal and reproductive health services and maternal and perinatal
694 mortality. *South Afr Health Rev*, 2022.
- 695 20. Moodley Y, Tomita A, de Oliveira T, Tanser F. HIV viral load and pregnancy loss:
696 results from a population-based cohort study in rural KwaZulu-Natal, South Africa.
697 *AIDS* 2021; **35**(5): 829-33.
- 698 21. Tukei VJ, Hoffman HJ, Greenberg L, et al. Adverse Pregnancy Outcomes Among HIV-
699 positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated
700 Compared With HIV-negative Women. *Pediatr Infect Dis J* 2021; **40**(9): 821-6.
- 701 22. Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide estimates
702 of stillbirth rates in 2015, with trends from 2000: a systematic analysis. *Lancet Glob
703 Health* 2016; **4**(2): e98-e108.
- 704 23. Tan CS, Collier AY, Yu J, et al. Durability of Heterologous and Homologous COVID-19
705 Vaccine Boosts. *JAMA Netw Open* 2022; **5**(8): e2226335.
- 706 24. Khoo NKH, Lim JME, Gill US, et al. Differential immunogenicity of homologous versus
707 heterologous boost in Ad26.COVS.2.S vaccine recipients. *Med* 2022; **3**(2): 104-18 e4.
- 708 25. Barouch DH, Stephenson KE, Sadoff J, et al. Durable Humoral and Cellular Immune
709 Responses 8 Months after Ad26.COVS.2.S Vaccination. *N Engl J Med* 2021; **385**(10):
710 951-3.
- 711 26. Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Durability of Immune Responses
712 After Boosting in Ad26.COVS.2.S-Primed Healthcare Workers. *Clin Infect Dis* 2023;
713 **76**(3): e533-e6.

- 714 27. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against
715 SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-
716 19/BNT162b2 vaccination. *Nat Med* 2021; **27**(9): 1525-9.
- 717 28. Garrett N, Tapley A, Andriesen J, et al. High Asymptomatic Carriage With the Omicron
718 Variant in South Africa. *Clin Infect Dis* 2022; **75**(1): e289-e92.
- 719 29. Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with
720 Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(14): 1314-26.
- 721

Total
N=501 230

SHERPA participants
N=12 342

Sisonke non-SHERPA
participants
N=488 888

N=1094 (8.9%) excluded

- 473 excluded due to data integrity at 1 site
- 125 could not be linked to their original Sisonke ID
- 142 received >2 Ad26.COVID.S before mRNA 1273
- 113 received BNT162b2 before mRNA-1273
- 117 received Ad26.COVID.S after earliest date of mRNA-1273 administration
- 124 Inappropriate enrolment

N=75 727 (15.5%) excluded


- 22 168 received >2 Ad26.COVID.S
- 48 368 received BNT162b2
- 5 191 received Ad26.COVID.S after earliest date of mRNA 1273 administration

N=11 248 (91.1%) included in the analyses

- 5 102 received Ad26.COVID.S + mRNA 1273
- 6 146 received Ad26.COVID.S x 2 + mRNA 1273






N= 413 161 (84.5 %) included in the analyses

- 185 676 received Ad26.COVID.S
- 227 485 received Ad26.COVID.S X2



A

	Ad26.COVS.2.S (1 prior dose)	Ad26.COVS.2.S (2 prior doses)
n	28	24
Age (med, IQR)	37 [30-51]	43 [37-47]
Gender (n, % female)	22 (84.6%)	20 (83.3%)
Days since first dose (med, IQR)	344 [335-368]	386 [340-460]
Days since second dose (med, IQR)	NA	188 [166-209]
HIV infection (n, %)	8 (31%)	8 (33.3%)
NC seropositive at BL (n, %)	23 (88.5%)	19 (79.2%)

B**C****D****E****F****G**